Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Innovative Medicines Initiative

This page shows the latest Innovative Medicines Initiative news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: success for Pfizer and Lilly arthritis drug, Darzalex soars, IMI launches Accelerator

Daily Brief: success for Pfizer and Lilly arthritis drug, Darzalex soars, IMI launches Accelerator

There is a substantial need for innovative new treatment options for osteoarthritis, as many patients are unable to find relief with currently available medicines and continue to suffer, ”said Ken Verburg, ... Europe launches antimicrobial research

Latest news

More from news
Approximately 5 fully matching, plus 55 partially matching documents found.

Latest Intelligence

  • 30 Women Leaders in UK Healthcare (part 2)

    She made major scientific contributions to neuroscience R&D within the pharmaceutical industry at GlaxoSmithkline, and also championed the vision for the Stevenage Bioscience Catalyst and theEuropean Innovative Medicines Initiative (IMI).

  • A quest for innovative solutions A quest for innovative solutions

    A quest for innovative solutions. UCB looks to the future through a PRISM. ... The innovative Medicines Initiative (IMI), with 5.3bn invested in 90 projects, is a barometer of the industry’s deep dive into technology at a time when ageing populations

  • Opening up innovation Opening up innovation

    The Immunology Network is probably one of the most innovative and powerful tools that I use to drive innovation and proliferation between different parts of the business, but also between GSK ... It has also been very active in the European Commission's

  • The world is our laboratory The world is our laboratory

    In January we announced the start of phase I clinical trials in the UK and US, production of 400, 000 vaccine regimens and formation of Innovative Medicines Initiative-funded consortia to ... That said, there is a rising demand for innovative medicines

  • The Heart of the Matter 7: Reality Dawns The Heart of the Matter 7: Reality Dawns

    Likewise, European pharmacovigilance legislation implemented in 2012 means the European Medicines Agency (EMA) is now requesting post-marketing observational studies as part of its approval processes. ... In tandem, as the limitations of the ‘

More from intelligence
Approximately 0 fully matching, plus 14 partially matching documents found.

Latest appointments

  • Innovative Medicines Initiative appoints executive director Innovative Medicines Initiative appoints executive director

    Innovative Medicines Initiative (IMI) has named Pierre Meulien as executive director, effective from September. ... Commenting on his appointment, Meulien said: “ I am delighted to have been selected to lead the second phase of the Innovative Medicines

  • IMI picks Ipsen's Marc de Garidel to chair governing board IMI picks Ipsen's Marc de Garidel to chair governing board

    The Innovative Medicines Initiative (IMI) has picked Ipsen's Marc de Garidel to take over as chair of its governing board from Roch Doliveux, who retired as CEO of UCB at ... Its second-phase IMI 2 programme aims to develop next generation vaccines,

  • IMI appoints new chair of scientific committee IMI appoints new chair of scientific committee

    Prof Maria Beatriz da Silva Lima has been elected chair of the Scientific Committee of the Innovative Medicines Initiative (IMI).

  • Hans Lennernas joins board of CMO Recipharm Hans Lennernas joins board of CMO Recipharm

    Prof Lennernäs is currently a professor of biopharmaceuticals at Uppsala University in Sweden, where he manages an Innovative Medicines Initiative (IMI) project called OrBiTo, which aims to improve the delivery of ... We are very pleased to welcome a

More from appointments
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • The Heart of the Matter 7: Reality Dawns

    Likewise, European pharmacovigilance legislation implemented in 2012 means the European Medicines Agency (EMA) is now requesting post-marketing observational studies as part of its approval processes. ... In tandem, as the limitations of the 'gold

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

The gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Quick links

Infographics

Multimedia